Pharmaceutical uses of optically pure (-)-bupropion
CA 2318920 A1 · Owner: Young, James W. · Inventors: Young, James W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions are disclosed utilizing the optically pure (-)-isomer of bupropion, which is a potent drug for treating depression Parkinson's , disease, obesity, weight gain bipolar disorders, attention-deficit disorders conduct disorders, phycho-sexual dysfunction bulimia, eating disorders or , specific food craving. The composition can be administered intravenously transdermally (patch) or orally, possibily in a sustained release form.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 28, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 28, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 28, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.